MetLife Investment Management’s Tarsus Pharmaceuticals TARS Stock Holding History

MetLife Investment Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.54M	Buy	24,493 +2,699	+12%	+$172K	0.01%	1299
2026 Q1	$1.53M	Buy	21,794 +120	+0.6%	+$8.38K	0.01%	1198
2025 Q4	$1.77M	Sell	21,674 -1,421	-6%	-$106K	0.01%	1139
2025 Q3	$1.37M	Hold	23,095	–	–	0.01%	1280
2025 Q2	$936K	Buy	23,095 +790	+4%	+$35.6K	0.01%	1349
2025 Q1	$1.15M	Sell	22,305 -373	-2%	-$18.4K	0.01%	1291
2024 Q4	$1.26M	Buy	22,678 +1,174	+5%	+$53.3K	0.01%	1299
2024 Q3	$707K	Hold	21,504	–	–	﹤0.01%	1591
2024 Q2	$584K	Buy	21,504 +5,964	+38%	+$201K	﹤0.01%	1637
2024 Q1	$565K	Hold	15,540	–	–	﹤0.01%	1607
2023 Q4	$315K	Buy	15,540 +2,772	+22%	+$46.3K	﹤0.01%	1963
2023 Q3	$227K	Hold	12,768	–	–	﹤0.01%	2133
2023 Q2	$231K	Buy	12,768 +2,094	+20%	+$33.3K	﹤0.01%	2186
2023 Q1	$134K	Hold	10,674	–	–	﹤0.01%	2432
2022 Q4	$156K	Hold	10,674	–	–	﹤0.01%	2398
2022 Q3	$183K	Hold	10,674	–	–	﹤0.01%	2354
2022 Q2	$156K	Buy	+10,674	New	+$160K	﹤0.01%	2473
2021 Q1	–	Sell	-3,250	Closed	-$134K	–	2333
2020 Q4	$134K	Buy	+3,250	New	+$92.6K	﹤0.01%	2169

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MetLife Investment Management's TARS Position: Q2 2026 in Review

MetLife Investment Management increased its Tarsus Pharmaceuticals (TARS) stake by 12% in Q2 2026, buying an estimated $172K and bringing the position to 24,493 shares worth $1.54M. The position accounts for 0.01% of the portfolio, ranked #1299.

MetLife Investment Management first reported a position in TARS in Q4 2020 and has held it in 18 quarters since. The position peaked at $1.77M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

MetLife Investment Management held 24,493 shares of Tarsus Pharmaceuticals worth $1.54M as of Q2 2026.
MetLife Investment Management bought 2,699 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $172K.
Tarsus Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1299 holding.
MetLife Investment Management first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 18 quarters since.
MetLife Investment Management's Tarsus Pharmaceuticals position peaked at $1.77M in Q4 2025.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.